Last edition
News about "FDA Approves New Therapy for Dravet Syndrome"
FDA Approves New Therapy for Dravet Syndrome
The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting seizures
FDA Approves New Therapy For Dravet Syndrome | 29/06/2020 | By Darshana | 437
FDA Approves New Therapy for Dravet Syndrome
The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting seizures
FDA Approves New Therapy For Dravet Syndrome | 29/06/2020 | By Darshana | 437
FDA Approves New Therapy for Dravet Syndrome
The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting seizures
FDA Approves New Therapy For Dravet Syndrome | 29/06/2020 | By Darshana | 437
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy